Session Details
[1S10a]Frontiers in neuronal homeostasis in aging and neurodegenerative diseases This symposium was supported by the AMED Strategic Promotion Program for
Translational Research, the Takeda Science Foundation for Pharmaceutical
Research Continuous Grants, and the Tohoku University Young Leaders
Overseas Program.
Tue. Aug 1, 2023 2:00 PM - 4:00 PM JST
Tue. Aug 1, 2023 5:00 AM - 7:00 AM UTC
Tue. Aug 1, 2023 5:00 AM - 7:00 AM UTC
Room 10 Meeting Room 4
Organizer: Ichiro Kawahata (Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University), David Finkelstein (Parkinson's Disease Laboratory, Florey Institute of Neuroscience and Mental Health, University of Melbourne)
With the advent of a super-aging society, the increase in age-related diseases has become a social problem. The causes of aging-dependent loss of neuronal function are still unknown. We have identified a signaling network and novel regulatory systems focusing on unique biomarkers to understand how homeostasis of neural function is maintained and lost. In this symposium, we will review the latest data on the regulatory mechanisms of neuronal homeostasis and discuss their physiological significance in disease and their therapeutic applications.
[1S10a-01]Pathogenic impact of fatty acid-binding protein 3 in neuronal homeostasis and the therapeutic potential for Lewy body diseases
○Ichiro Kawahata1, Kohji Fukunaga1,2 (1. Grad Sch Pharm Sci, Tohoku Univ, Sendai, Japan, 2. BRI Pharma Inc., Sendai, Japan)
[1S10a-02]Epsin2 regulates alpha-synuclein propagation via FABP7 in multiple system atrophy
○an cheng1,2, Kohji Fukunaga1 (1. Tohoku University, 2. University of California San Francisco)
[1S10a-03]Using compounds that decrease brain iron to reduce alpha-synuclein mediated neurodegeneration
○David I Finkelstein1 (1. Parkinson's Disease Laboratory, Florey Institute of Neuroscience and Mental Health, University of Melbourne)
[1S10a-04]Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction
○Ying-Mei Lu1, Ya-Ping Lu1, Xiang Chen2, Xiu-Xiu Liu2, Yi Shi1, Zhao-Cong Wei1, Li-Li Feng2, Quan Jiang3, Wei-Feng Ye4, Takuya Sasaki5, Kohji Fukunaga5, Yong Ji2, Feng Han2 (1. School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China, 2. School of Pharmacy, Nanjing Medical University, Nanjing, China, 3. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China, 4. Department of Pharmacy, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China, 5. Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan)
[1S10a-05]Pathology of synapse-proteasome signaling in Alzheimer disease and aging
○Kohji Fukunaga1,2 (1. Tohoku University, 2. BRI Pharma Inc.)